{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:19:42Z","timestamp":1775841582458,"version":"3.50.1"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007343","name":"Universit\u00e0 degli Studi di Brescia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007343","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>At the beginning of the SARS-CoV-2 pandemic, there was a lack of information about the infection\u2019s impact on pregnancy and capability to induce <jats:italic>de novo<\/jats:italic> autoantibodies. It soon became clear that thrombosis was a manifestation of COVID-19, therefore the possible contribution of <jats:italic>de novo<\/jats:italic> antiphospholipid antibodies (aPL) raised research interest. We aimed at screening SARS-CoV-2 positive pregnant patients for aPL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The study included consecutive pregnant women who were hospitalized in our Obstetric Department between March 2020 and July 2021 for either a symptomatic SARS-CoV-2 infection or for other reasons (obstetric complications, labour, delivery) and found positive at the admission nasopharyngeal swab. All these women underwent the search for aPL by means of Lupus Anticoagulant (LA), IgG\/IgM anti-cardiolipin (aCL), IgG\/IgM anti-beta2glycoprotein I (aB2GPI). Data about comorbidities, obstetric and neonatal complications were collected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>151 women were included. Sixteen (11%) were positive for aPL, mostly at low titre. Pneumonia was diagnosed in 20 women (5 with positive aPL) and 5 required ICU admission (2 with positive aPL). Obstetric complications occurred in 10\/16 (63%) aPL positive and in 36\/135 (27%) negative patients. The occurrence of HELLP syndrome and preeclampsia was significantly associated with positive aPL (p=0,004). One case of maternal thrombosis occurred in an aPL negative woman. aPL positivity was checked after at least 12 weeks in 7\/16 women (44%): 3 had become negative; 2 were still positive (1 IgG aB2GPI + IgG aCL; 1 IgM aB2GPI); 1 remained positive for IgG aCL but became negative for aB2GPI; 1 became negative for LA but displayed a new positivity for IgG aCL at high titre.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The frequency of positive aPL in pregnant women with SARS-CoV-2 infection was low in our cohort and similar to the one described in the general obstetric population. aPL mostly presented as single positive, low titre, transient antibodies. The rate of obstetric complications was higher in aPL positive women as compared to negative ones, particularly hypertensive disorders. Causality cannot be excluded; however, other risk factors, including a full-blown picture of COVID-19, may have elicited the pathogenic potential of aPL and contributed themselves to the development of complications.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.953043","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T11:06:28Z","timestamp":1663239988000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Frequency of positive antiphospholipid antibodies in pregnant women with SARS-CoV-2 infection and impact on pregnancy outcome: A single-center prospective study on 151 pregnancies"],"prefix":"10.3389","volume":"13","author":[{"given":"Giorgia Ingrid","family":"Gozzoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elda","family":"Piovani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Negri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Mascherpa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossana","family":"Orabona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Zanardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Zatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Piantoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Grazia","family":"Lazzaroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesare","family":"Tomasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Prefumo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Tincani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Andreoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.852777","article-title":"Risk of thrombosis, pregnancy morbidity or death in antiphospholipid syndrome","volume":"9","author":"Killian","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"910751","DOI":"10.1155\/2014\/910751","article-title":"Genetic aspects of preeclampsia and the HELLP syndrome","volume":"2014","author":"Haram","year":"2014","journal-title":"J Pregnancy"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2021.1050","article-title":"Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: The INTERCOVID multinational cohort study","volume":"175","author":"Villar","year":"2021","journal-title":"JAMA Pediatr"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2021.05.014","article-title":"Preeclampsia and COVID-19: Results from the INTERCOVID prospective longitudinal study","volume":"225","author":"Papageorghiou","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMra1705454","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"379","author":"Garcia","year":"2018","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jaut.2018.02.002","article-title":"Beyond thrombosis: Anti-\u03b22GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome","volume":"90","author":"Chighizola","year":"2018","journal-title":"J Autoimmun"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15047","article-title":"Guidance from the scientific and standardization committee for lupus anticoagulant\/antiphospholipid antibodies of the international society on thrombosis and haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation","volume":"18","author":"Devreese","year":"2020","journal-title":"J Thromb Haemost"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/uog.15884","article-title":"Consensus definition of fetal growth restriction: A Delphi procedure","volume":"48","author":"Gordijn","year":"2016","journal-title":"Ultrasound Obstet Gynecol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2021.11.1357","article-title":"Clinical opinion: The diagnosis and management of suspected fetal growth restriction: an evidence-based approach","volume":"226","author":"Lees","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.preghy.2018.05.004","article-title":"The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice","volume":"13","author":"Brown","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60932-6","article-title":"International standards for newborn weight, length, and head circumference by gestational age and sex: The newborn cross-sectional study of the INTERGROWTH-21st project","volume":"384","author":"Villar","year":"2014","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B13","article-title":"Role of infectious agents in systemic rheumatic diseases","volume":"26","author":"Amital","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"B14","article-title":"Infections, connective tissue diseases and vasculitis","volume":"26","author":"Avcin","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2007.10.001","article-title":"Antiphospholipid antibodies, antiphospholipid syndrome and infections","volume":"7","author":"S\u00e8ne","year":"2008","journal-title":"Autoimmun Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05724-5","article-title":"Are antiphospholipid antibodies just a common epiphenomenon or are they causative of immune-mediated coagulopathy in COVID-19","volume":"40","author":"Castillo-Mart\u00ednez","year":"2021","journal-title":"Clin Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.584241","article-title":"Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome","volume":"11","author":"Borghi","year":"2020","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.05.006","article-title":"Complement activation in patients with COVID-19: A novel therapeutic target","volume":"146","author":"Cugno","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s12016-008-8103-0","article-title":"Infections and the antiphospholipid syndrome","volume":"36","author":"Garc\u00eda-Carrasco","year":"2009","journal-title":"Clin Rev Allergy Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa203","article-title":"EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies","volume":"60","author":"Pregnolato","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(89)90522-X","article-title":"The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population","volume":"161","author":"Lockwood","year":"1989","journal-title":"Am J Obstet Gynecol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3109\/00016349209006228","article-title":"Lupus anticoagulant and anticardiolipin antibodies in an obstetric population","volume":"71","author":"Rix","year":"1992","journal-title":"Acta Obstet Gynecol Scand"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/0029-7844(95)00247-O","article-title":"Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy","volume":"86","author":"Yasuda","year":"1995","journal-title":"Obstet Gynecol."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1993.tb15105.x","article-title":"Antiphospholipid antibodies in pregnancy: Prevalence and clinical associations","volume":"100","author":"Pattison","year":"1993","journal-title":"Br J Obstet Gynaecol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)90889-O","article-title":"Pre-eclampsia: More than pregnancy-induced hypertension","volume":"341","author":"Roberts","year":"1993","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400322","article-title":"Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation","volume":"40","author":"Del Papa","year":"1997","journal-title":"Arthritis Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/s0301-2115(97)02736-x","article-title":"Anti-beta 2 glycoprotein I antibodies in a general obstetric population: Preliminary results on the prevalence and correlation with pregnancy outcome. Anti-beta2 glycoprotein I antibodies are associated with some obstetrical complications, mainly preeclampsia-eclampsia","volume":"73","author":"Faden","year":"1997","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/v14030458","article-title":"Stillbirth after COVID-19 in unvaccinated mothers can result from SARS-CoV-2 placentitis, placental insufficiency, and hypoxic ischemic fetal demise, not direct fetal infection: Potential role of maternal vaccination in pregnancy","volume":"14","author":"Schwartz","year":"2022","journal-title":"Viruses"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.11.013","article-title":"The geoepidemiology of the antiphospholipid antibody syndrome","volume":"9","author":"Biggioggero","year":"2010","journal-title":"Autoimmun Rev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2020.35.e35","article-title":"Epidemiology of antiphospholipid syndrome in Korea: A nationwide population-based study","volume":"35","author":"Hwang","year":"2020","journal-title":"J Korean Med Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/art.40901","article-title":"The epidemiology of antiphospholipid syndrome: A population-based study","volume":"71","author":"Duarte-Garc\u00eda","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15053","article-title":"The prevalence of antiphospholipid antibodies in women with late pregnancy complications and low-risk for chromosomal abnormalities","volume":"18","author":"Foddai","year":"2020","journal-title":"J Thromb Haemost"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0b013e328304dffc","article-title":"Thrombophilic dimension of recurrent fetal loss in Indian patients","volume":"19","author":"Vora","year":"2008","journal-title":"Blood Coagul Fibrinolysis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22066","article-title":"Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: A critical review of the literature","volume":"65","author":"Andreoli","year":"2013","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"B35","doi-asserted-by":"publisher","first-page":"103060","DOI":"10.1016\/j.autrev.2022.103060","article-title":"Drug-induced antiphospholipid syndrome: Analysis of the WHO international database","volume":"21","author":"G\u00e9rardin","year":"2022","journal-title":"Autoimmun Rev"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.953043\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T11:06:36Z","timestamp":1663239996000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.953043\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,15]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2022.953043"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.953043","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,15]]},"article-number":"953043"}}